Neovasc is Creating
for the Treatment of
Advanced Heart Disease
PR Martine Gilard de la Société Française de Cardiologie annonce le lancement officiel du registre « France Réducteur ».
A LEADER IN CARDIOVASCULAR INNOVATION
Neovasc is a leader in the development of minimally invasive therapies for two of the most vexing challenges in cardiovascular care: refractory angina and mitral valve regurgitation.
The company is committed to clinical rigor and collaborates with researchers and clinicians in Canada, the United States, Europe, and the Middle East. Our products, the Reducer™ and Tiara™ systems, represent the forefront of innovation in treating advanced heart disease.
Reducer is CE-marked for use in the EU and is FDA approved for investigational use in the US. Tiara is not commercially available and is currently being evaluated in two ongoing clinical trials.
Headquartered in Vancouver, BC and Minneapolis, MN, Neovasc is publicly traded on both the NASDAQ and the Toronto Stock Exchange (NVCN).
13700 Mayfield Place #2135
Richmond BC V6V 2E4
900 Long Lake Road
New Brighton, MN 55112
900 Long Lake Road
New Brighton, MN 55112
LEADERSHIP AND GUIDANCE
Prof. Shmuel Banai
Fred Colen is a seasoned business executive with years of experience leading small, medium and large medical device businesses throughout the world. Fred has been a successful business innovator in commercialization of new medical technology products. He was President/CEO of BeneChill, a brain cooling company and President of the Boston Scientific Cardiac Rhythm Management Group. Additionally he served as Boston Scientific’s Chief Technology Officer for eight years. Born and raised in the Netherlands, Fred obtained a master's degree in Electrical Engineering with specialization in BioMedical Technology from the RWTH Aachen, Germany. He has served on several boards: Mölnlycke Healthcare, Middle Peak Medical and College of Science & Engineering at the University of Minnesota.
Bill has extensive leadership experience in both interventional cardiology and structural heart disease. Prior to joining Neovasc, he served on the leadership team at Abbott Vascular. During his tenure at Abbott, Bill worked as Divisional Vice President of Global Marketing, and Head of Customer and New Market Insights. He previously served as Vice President of Global Cardiovascular Therapies for St. Jude Medical and joined Abbott through the acquisition of the company. While at St. Jude Medical, Bill oversaw marketing and strategy for the structural heart and vascular portfolios. Prior to joining St. Jude Medical, he was Vice President, Global Marketing at Bard Peripheral Vascular and he spent 13 years at Boston Scientific in a variety of domestic and international sales and marketing roles focused primarily on cardiovascular interventions. Bill holds a B.S. in Business Administration and Marketing from the University of Colorado at Boulder.
Chris has almost 20 years of finance and accounting experience in public practice and in public and private companies, most recently focused in the medical device sector. Previous experience includes financial leadership roles with large automotive and telecom firms in which he developed deep expertise in the development and management of sophisticated financial systems. A highly sought after consultant for biotechnology startups, Chris accepted the role of Chief Financial Officer at Neovasc and was instrumental in the initial and ongoing development of Neovasc as a publicly traded company. He received his designation as a Chartered Accountant from the Institute of Chartered Accountants of England and Wales and articled with KPMG before moving to Canada from England in 1998. He has an honors degree in Economics from Swansea University and a post graduate diploma from Keble College, Oxford.
Lisa has more than 20 years of experience in medical device regulatory affairs. Her product and therapy experience has spanned medical devices from cardiac rhythm management to vascular support, pulmonary artery pressure monitoring, cardiac occluders, heart valves and most recently, structural heart products. Lisa joined Neovasc to provide Regulatory leadership in Angina Therapies in July 2021, and brings deep regulatory experience in U.S. and international markets. Creative and collaborative regulatory strategies drive her regulatory approach with the best interest of patients always at the forefront. Lisa earned her Bachelor of Science in Organizational Behavior with a General Engineering minor from the United States Air Force Academy. She served nearly ten years on active duty in the US Air Force while obtaining her Master of Science as well. She considers her regulatory work as a continuation of her service to improving lives.
Sarah Gallagher joined Neovasc as the Vice President of Clinical Affairs in June of 2021, bringing with her 20 years of medical device clinical research experience. Prior to joining Neovasc, Sarah held leadership roles at Medtronic in Interventional Pain, Neuromodulation, and Cardiac Rhythm Management, and St. Jude Medical in Structural Heart. During her tenure she held roles with increasing responsibility in clinical research and clinical operations. She has developed and executed both pre and post-market clinical trials and supported regulatory approvals globally. Sarah holds a Bachelor of Applied Arts in Exercise Science, a Bachelor of Arts in Psychology, from the University of Minnesota, and Master of Science in Technology Management from the University of St. Thomas.
John Panton has over 30 years of engineering experience spread over the Total Product Life Cycle, in small, medium and large organizations and across different industrial sectors: medical devices, semiconductor, oil and gas, telecommunications, consumer electronics and military avionics. In England, John held various engineering roles of increasing responsibility specializing in new product introduction; in R&D, product and process design and development, manufacturing engineering, process engineering and product engineering. In 2005, John started his Canadian career as a Quality professional, as the Quality Assurance Manager of a start-up company serving semiconductor Fortune 500 customers. He then moved to a Class 2 reusable medical device company initially as Quality and Regulatory Manager and then later to Global Director of Quality Systems, where he had responsibility for sites in Canada, US, Europe and Australia. John joined Neovasc in May 2015 as Director of Quality Systems, moved to VP of Quality in November, 2017 and was named Chief Quality Officer in 2020. John holds a Post Graduate Diploma in Microelectronics Technology and Applications from Middlesex University, and a Higher National Diploma in Physics from Portsmouth Polytechnic.
Prof. Shmuel Banai
One of Israel’s leading cardiologists and a productive researcher, Professor Shmuel Banai was Medical Director of Neovasc Medical Ltd., one of the predecessor companies to Neovasc Inc., where he now fulfills the role of Medical Director. Prof. Banai is the Director of the Division of Cardiology and the Head of Interventional Cardiology at the Tel Aviv Medical Center, Tel Aviv, Israel. He is a full academic Professor of Cardiology at the Tel Aviv University, Sackler School of Medicine, head of the Nicholas and Elizabeth Slezak Super Center for Cardiac Research and Biomedical Engineering, and the Walton Chair of Interventional Cardiology at the Tel Aviv University. His main research interests are vessel wall biology and physiology, myocardial microcirculation, atherosclerosis, vulnerable plaque, pharmacological treatment of restenosis, anti-thrombotic therapy, and device-based therapy for refractory angina. Professor Banai is the author of more than 200 peer-reviewed papers and book chapters and has participated in many clinical and pre-clinical research studies in the field of cardiology, interventional cardiology, and pharmacotherapy.
Steve Rubin, Chairman